Pacific Biosciences Of California (PACB) EBT Margin Growth (3y) (2013 - 2026)
Pacific Biosciences Of California (PACB) EBT Margin Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | -305.00 |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | -9.00 |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 55.00 |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 923.00 |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -480.00 |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 1,391.00 |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 2,114.00 |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | -176.00 |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Pacific Biosciences Of California | 428.15 Mn | 152.18 Mn | 12.84 Mn | 20,450.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 20,450.00 |
| Dec 31, 2025 | 21,853.00 |
| Sep 30, 2025 | 14,036.00 |
| Jun 30, 2025 | 9,594.00 |
| Mar 31, 2025 | -90,195.00 |
| Dec 31, 2024 | 19,607.00 |
| Jun 30, 2024 | -19,317.00 |
| Mar 31, 2024 | -7,027.00 |
| Dec 31, 2023 | -41,792.00 |
| Sep 30, 2023 | -1,505.00 |
| Jun 30, 2023 | 32,854.00 |
| Mar 31, 2023 | -1,059.00 |
| Dec 31, 2022 | -23,900.00 |
| Sep 30, 2022 | -10,690.00 |
| Jun 30, 2022 | -9,966.00 |
| Mar 31, 2022 | -5,126.00 |
| Dec 31, 2021 | -2,917.00 |
| Jun 30, 2021 | -15,263.00 |
| Mar 31, 2021 | 19,509.00 |
| Dec 31, 2020 | 36,098.00 |